As CMS weighs policy options for setting 340B drug pay rates, it is being tugged in different directions by 340B hospitals, for-profit hospitals that don’t participate in the drug discount program, physicians and drug makers. 340B hospitals argue CMS lacks authority to pay them less than others for Part B drugs, but for-profit hospitals -- which don’t participate in the drug discount program -- agree with the 340B cuts and say CMS can’t legally recoup funds from them if it...